PRLD

Prelude Therapeutics Incorporated operates as a clinical-stage precision oncology company developing targeted cancer therapies. Headquartered in Wilmington, Delaware, the company focuses on discovering and creating small molecule therapies designed to target key drivers of cancer cell growth and resistance mechanisms. Prelude's pipeline centers on precision medicines for genomically defined cancers, with lead programs targeting CDK4/6, SMARCA2/4, and other critical pathways in tumor biology. The company's most advanced candidates include PRT3789, a SMARCA2-selective degrader in Phase 1 clinical trials for SMARCA4-mutant cancers, and PRT2527, a CDK9 inhibitor for MYC-altered solid tumors and blood cancers. Prelude also develops PRT1419, targeting the Cereblon pathway in hematologic malignancies. The company employs approximately 100 people and maintains research operations focused on structure-based drug design and medicinal chemistry. In December 2024, Prelude announced a strategic review process to explore alternatives for maximizing shareholder value, including potential mergers, asset sales, or other strategic transactions. The company collaborates with academic institutions and maintains partnerships to advance its precision medicine platform. Founded in 2016, Prelude went public in 2020 and trades on NASDAQ under the ticker PRLD. The company continues to enroll patients in multiple clinical trials while managing its cash resources to fund ongoing development programs.